ArticleJournal of neuro-oncology2026
A patient-derived organoid platform for predominantly posterior fossa adult ependymoma: histopathologic preservation, culture-associated transcriptomic remodeling, and in vivo tumorigenicity.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
purposeWell-characterized patient-derived models of adult ependymoma (EPN) remain limited. We established a patient-derived organoid (PDO) platform from adult EPN and evaluated its histopathologic and immunophenotypic characteristics, transcriptomic relationship to parental tumors, and in vivo tumorigenicity.
methodsFresh surgical specimens from 22 adult patients with EPN were processed for PDO establishment. Tumor-PDO fidelity was assessed by histology and immunofluorescence. Three matched tumor-PDO pairs underwent RNA sequencing followed by paired differential-expression, gene-set enrichment, microenvironmental signature, and ESTIMATE analyses. Selected PDO models were further evaluated by subcutaneous and intracranial xenografting.
resultsPDOs were successfully established from 20 of 22 specimens (90.9%). Established PDOs broadly retained parental tumor morphology and expression of major ependymoma-associated and neural/progenitor markers. Selected morphologic and immunophenotypic features remained detectable during prolonged culture. Transcriptomic profiling of three matched tumor-PDO pairs demonstrated high global expression similarity (Pearson r = 0.84-0.88) together with substantial culture-associated remodeling. Endothelial signatures and ESTIMATE-derived stromal scores were reduced in all three PDOs, whereas other immune and stromal signatures showed patient-specific changes. Paired transcriptomic analysis further identified enrichment of ribosome/translation and oxidative-phosphorylation programs in PDOs, accompanied by reduced cilia- and axoneme-associated programs. Selected PDO-derived models demonstrated tumorigenic capacity in subcutaneous and intracranial settings.
conclusionAdult EPN can be propagated efficiently as PDOs that retain selected tumor-associated features while undergoing measurable transcriptional and microenvironment-associated adaptation to ex vivo culture. Selected models also retained tumorigenic capacity in vivo. These models provide a complementary experimental platform for studying adult EPN biology.
Indexed as
Identifiers
42809120What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.